Literature DB >> 19861925

Cancer stem cells.

Charles Rudin1, John Minna.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19861925      PMCID： PMC3391568          DOI： 10.1097/01.JTO.0000361758.17413.7c

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  19 in total

1.  In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor.

Authors:  Z Gunnur Dikmen; Ginelle C Gellert; Shalmica Jackson; Sergei Gryaznov; Robert Tressler; Pakize Dogan; Woodring E Wright; Jerry W Shay
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

2.  Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.

Authors:  Mariam Dohadwala; Seok-Chul Yang; Jie Luo; Sherven Sharma; Raj K Batra; Min Huang; Ying Lin; Lee Goodglick; Kostyantyn Krysan; Michael C Fishbein; Longsheng Hong; Chi Lai; Robert B Cameron; Robert M Gemmill; Harry A Drabkin; Steven M Dubinett
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

3.  Lipid modification of GRN163, an N3'-->P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition.

Authors:  Brittney-Shea Herbert; Ginelle C Gellert; Amelia Hochreiter; Krisztina Pongracz; Woodring E Wright; Daria Zielinska; Allison C Chin; Calvin B Harley; Jerry W Shay; Sergei M Gryaznov
Journal:  Oncogene       Date:  2005-08-04       Impact factor: 9.867

4.  Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Authors:  Martin J Edelman; Dee Watson; Xiaofei Wang; Carl Morrison; Robert A Kratzke; Scott Jewell; Lydia Hodgson; Ann M Mauer; Ajeet Gajra; Gregory A Masters; Michelle Bedor; Everett E Vokes; Mark J Green
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

5.  Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model.

Authors:  Naomi Shimazaki; Noriko Togashi; Masaharu Hanai; Takeshi Isoyama; Kunio Wada; Takashi Fujita; Kosaku Fujiwara; Shinichi Kurakata
Journal:  Eur J Cancer       Date:  2008-05-27       Impact factor: 9.162

6.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.

Authors:  Maria M Ho; Alvin V Ng; Stephen Lam; Jaclyn Y Hung
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

Review 7.  Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment.

Authors:  Jay M Lee; Jane Yanagawa; Katherine A Peebles; Sherven Sharma; Jenny T Mao; Steven M Dubinett
Journal:  Crit Rev Oncol Hematol       Date:  2008-03-04       Impact factor: 6.312

8.  Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.

Authors:  Karen L Reckamp; Brian K Gardner; Robert A Figlin; David Elashoff; Kostyantyn Krysan; Mariam Dohadwala; Jenny Mao; Sherven Sharma; Landon Inge; Ayyappan Rajasekaran; Steven M Dubinett
Journal:  J Thorac Oncol       Date:  2008-02       Impact factor: 15.609

9.  Identification and expansion of the tumorigenic lung cancer stem cell population.

Authors:  A Eramo; F Lotti; G Sette; E Pilozzi; M Biffoni; A Di Virgilio; C Conticello; L Ruco; C Peschle; R De Maria
Journal:  Cell Death Differ       Date:  2007-11-30       Impact factor: 15.828

Review 10.  Telomerase and cancer therapeutics.

Authors:  Calvin B Harley
Journal:  Nat Rev Cancer       Date:  2008-03       Impact factor: 60.716
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.